Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Mi Na | - |
dc.contributor.author | Seo, Hee Jeong | - |
dc.contributor.author | Kim, Yoonji | - |
dc.contributor.author | Seo, n Hee Seo | - |
dc.contributor.author | Rhim, Hyewhon | - |
dc.contributor.author | Cho, Yong Seo | - |
dc.contributor.author | Cha, Joo Hwan | - |
dc.contributor.author | Koh, Hun Yeong | - |
dc.contributor.author | Choo, Hyunah | - |
dc.contributor.author | Pae, Ae Nim | - |
dc.date.accessioned | 2024-01-21T01:34:59Z | - |
dc.date.available | 2024-01-21T01:34:59Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2007-01-01 | - |
dc.identifier.issn | 0968-0896 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/134749 | - |
dc.description.abstract | T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pains. Since the withdrawal of mibefradil, a T-type calcium channel blocker, there have been a lot of efforts to develop T-type calcium channel blockers. A small molecule library of dioxoquinazoline carboxamide derivatives containing 155 compounds was designed, synthesized, and biologically evaluated for T-type calcium channel blocking activity. Among those compounds synthesized, the compound In shows the most potent T-type calcium current blocking activity with an IC50 value of 1.52 mu M, which is comparable to that of mibefradil. (c) 2006 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | BIOLOGICAL EVALUATION | - |
dc.subject | CA2+ CHANNELS | - |
dc.title | Novel T-type calcium channel blockers: Dioxoquinazoline carboxamide derivatives | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmc.2006.09.051 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY, v.15, no.1, pp.365 - 373 | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY | - |
dc.citation.volume | 15 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 365 | - |
dc.citation.endPage | 373 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000243087200035 | - |
dc.identifier.scopusid | 2-s2.0-33750952104 | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
dc.subject.keywordPlus | CA2+ CHANNELS | - |
dc.subject.keywordAuthor | T-type calcium channel blockers | - |
dc.subject.keywordAuthor | dioxoquinazoline carboxamide derivatives | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.